Companies Dominating the Cryptococcal Antigen Lateral Flow Assay Test Landscape
- Kestrel Biosciences LIC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Alere Inc.
- BioMerieux
- Danaher Corporation
- Forsite Diagnostics
- Merck Millipore
- Qiagen
- Roche Diagnostics
- Hologic (Gen-Probe)
- Siemens Healthcare
Browse Key Market Insights with Data Illustration:
In the News
- April 2021 - For the past ten years, the industry-leading Cryptococcal Antigen (CrAg) Lateral Flow Assay (LFA) from IMMY has helped doctors diagnose cryptococcal infections all over the world. Immunocompromised individuals, such as those infected with HIV, are susceptible to cryptococcal infections, and early identification can greatly enhance therapeutic results. Before the onset of cryptococcal meningitis, the CrAg® LFA can identify cryptococcal antigens in the blood of asymptomatic patients, allowing for the proactive treatment of CrAg-positive individuals. This year commemorates the tenth anniversary of this potentially life-saving test, which, when compared to culture or India ink microscopy, has the advantages of rapid turnaround and sensitivity, revolutionizing the detection of an opportunistic fungal infection.
- January 2024 - In October 2023, bioMérieux inked a new Research Master Agreement with the University of Pittsburgh (Pennsylvania, USA), which was in line with its business growth and regional expansion. This three-year contract presents an excellent chance to lead the way in the creation of novel diagnostic approaches in the infectious disease space. Pitt's Division of Clinical Microbiology and Division of Infectious Diseases is working with the bioMérieux Analytical and Sequencing team on this first collaborative project, which has a sequencing focus.
